Shopping Cart
- Remove All
- Your shopping cart is currently empty
DLK-IN-1 is a selective oral active inhibitor of bisleucine zipper kinase (DLK, MAP3K12) with Ki of 3 nM. DLK-IN-1 is active in the Alzheimer's disease model, retains excellent CNS permeability, and after multiple days of administration, its concentration exceeds the concentration required for DLK inhibition in the brain, so it has good tolerance Acceptability.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $523 | 10-14 weeks | |
25 mg | $1,750 | 10-14 weeks | |
50 mg | $2,280 | 10-14 weeks | |
100 mg | $3,270 | 10-14 weeks |
Description | DLK-IN-1 is a selective oral active inhibitor of bisleucine zipper kinase (DLK, MAP3K12) with Ki of 3 nM. DLK-IN-1 is active in the Alzheimer's disease model, retains excellent CNS permeability, and after multiple days of administration, its concentration |
Targets&IC50 | DLK:ki:3 nM |
Molecular Weight | 423.43 |
Formula | C20H24F3N5O2 |
Cas No. | 1620574-24-4 |
Relative Density. | 1.59 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 62.5 mg/mL (147.60 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.